Potent modulation of the CepR quorum sensing receptor and virulence in a *Burkholderia cepacia* complex member using non-native lactone ligands

Betty L. Slinger¹, Jacqueline J. Deay², Josephine R. Chandler² & Helen E. Blackwell¹

The *Burkholderia cepacia* complex (Bcc) is a family of closely related bacterial pathogens that are the causative agent of deadly human infections. Virulence in Bcc species has been shown to be controlled by the CepI/CepR quorum sensing (QS) system, which is mediated by an N-acyl L-homoserine lactone (AHL) signal (C8-AHL) and its cognate LuxR-type receptor (CepR). Chemical strategies to block QS in Bcc members would represent an approach to intercept this bacterial communication process and further delineate its role in infection. In the current study, we sought to identify non-native AHLs capable of agonizing or antagonizing CepR, and thereby QS, in a Bcc member. We screened a library of AHL analogs in cell-based reporters for CepR, and identified numerous highly potent CepR agonists and antagonists. These compounds remain active in a Bcc member, *B. multivorans*, with one agonist 250-fold more potent than the native ligand C8-AHL, and can affect QS-controlled motility. Further, the CepR antagonists prolong *C. elegans* survival in an infection model. These AHL analogs are the first reported non-native molecules that both directly modulate CepR and impact QS-controlled phenotypes in a Bcc member, and represent valuable chemical tools to assess the role of QS in Bcc infections.

Members of the *Burkholderia cepacia* complex (Bcc) have emerged as multi-drug resistant opportunistic pathogens in human infections, including pulmonary infection associated with cystic fibrosis (CF)³ and central nervous system infections⁴. The Bcc consists of more than 17 closely-related species that are mostly found in the environment and has grown to include not only plant, animal, and human pathogens, but also bioremediation and biocontrol strains. While all Bcc members have the potential to infect CF patients⁵, the most commonly isolated species from these patients are *B. cenocepacia* and *B. multivorans*⁶. Infections are especially problematic due to these species having high levels of intrinsic and acquired resistance to many clinically-relevant antibiotics (recently reviewed in ref.⁷). Furthermore, promising new antibiotics for the Bcc, such as Q22⁸, were subsequently shown to increase resistance after treatment and had toxicity effects in the host⁹. Consequently, new therapeutic strategies are needed to treat Bcc infections.

Because pathogenicity and virulence phenotypes are under the control of quorum sensing (QS) in many common bacterial pathogens, including the Bcc, QS inhibition has attracted interest as a potential strategy to combat bacterial infections⁹. Quorum sensing (QS) is a bacterial cell-cell signaling system based on small molecule or peptide signals, termed autoinducers. Proteobacteria commonly use diffusible N-acyl L-homoserine lactone (AHL) autoinducers, which are generated by LuxI-type synthases and sensed by cytoplasmic LuxR-type receptors. Signal concentration increases with cell density, and when a threshold population is achieved in a given environment, the QS signal will productively bind to its target receptor protein. This binding event will ultimately cause alterations in gene expression levels, allowing the bacteria to initiate group-beneficial behaviors. QS allows pathogens to coordinate production of factors that increase infectivity (e.g., toxins, exoenzymes, and biofilm matrix components)⁹. There is evidence to suggest that targeting the QS system may put less selective pressure on these...
IC50 values and many of the CepR agonists are more potent than CepR’s native ligand, C8-AHL, with EC50 values discovery of a set of highly potent CepR modulators. The CepR antagonists have sub- to single-digit micromolar receptor, respectively. QS is a central regulator for the expression of pathogenic traits in the Bcc12, and the CepI/CepR circuit has been demonstrated to control virulence in various eukaryotic models of Bcc infection, including C. elegans13, fruit fly (D. melanogaster)14, rats, and mice15,16. Furthermore, a functional QS system is maintained in chronic B. cenocepacia and B. multivorans CF-infections17, which is intriguing because the related LasR receptor from the commonly isolated CF-pathogen, Pseudomonas aeruginosa, can become non-functional during the course of chronic CF-infections18–20. This result underscores the likely importance of the CepI/CepR system to Burkholderia physiology and Bcc pathogenicity.

Methods to inhibit QS in the Bcc could be extremely valuable for both fundamental studies of the CepI/CepR system and for infection control. In addition, strategies that selectively target CepR in a mixed microbial setting could control the role of possible interspecies interactions via QS in polymicrobial infections or environments. Small molecules that agonize or antagonize CepI/CepR would represent one such strategy. Our laboratory has developed hundreds of synthetic AHLs and non-AHL-derived compounds that can either inhibit or activate LuxR-type receptors in many different species of Gram-negative bacteria. For example, these compounds have proven successful at modulating QS in P. aeruginosa (ligands targeting LasR, RhlR, or QscR)1,2,23, Acinetobacter baumannii (AbaR)23, Agrobacterium tumefaciens (TraR)23,25, Vibrio fischeri (LuxR)25, Chromobacterium violaceum (CvIR)26, Pectobacterium carotovora (ExpR1 and ExpR2)27, Pseudomonas syringae (AhIR)26, and Rhodopseudomonas palustris (RpaR)27. In the work outlined herein, we sought to apply our research strategy to identify chemical modulators of CepR and utilize these ligands to modulate QS, and thereby virulence, in a member of the Bcc.

To date, there has been limited research focused on developing compounds that target the CepI/CepR system, or modulate QS in general, in Bcc member species. In fact, we are only aware of five reported studies26–29. An early report by Weingart et al., provided some clues as to which structural features of naturally-occurring AHLs may affect CepR function30, and identified hexanoyl-HL and 5-hexynoyl-HL as having slight inhibitory effects on CepR at concentrations greater than 1 μM, although potency data (i.e., EC50 and IC50 values) were not reported. More recently, Scoffone and coworkers reported several diketopiperazine derivatives were CepI synthase inhibitors and increased survival of B. cenocepacia-infected Caenorhabditis elegans31. Other compounds have been shown to affect QS-controlled phenotypes in certain Bcc members. For example, Riedel and coworkers demonstrated that a hydrazide type compound (termed compound 3), could alter QS-controlled phenotypes in B. cenocepacia H11133. In addition, Brackman and colleagues discovered that two different compounds, baicalin hydrate32 and a triazole compound33, can reduce biofilm biomass (a QS-controlled phenotype) in B. cenocepacia and B. multivorans. However, in all of these studies, the molecular target of the compounds was not demonstrated, and it was subsequently discovered that baicalin hydrate likely targets bacterial respiration (not QS)34. These prior studies indicate that additional research is required to identify chemical tools to selectively target CepR.

Herein, we report the systematic screening of an AHL-based library in an E. coli CepR reporter strain and the discovery of a set of highly potent CepR modulators. The CepR antagonists have sub- to single-digit micromolar IC50 values and many of the CepR agonists are more potent than CepR’s native ligand, C8-AHL, with EC50 values below 1 nM in the reporter strain. These compounds remain active in a member of the Bcc, B. multivorans, and affect QS-controlled motility, with antagonists reducing motility by roughly 50%. Notably, our lead CepR antagonists increase the survival of C. elegans colonized by B. multivorans, suggesting that B. multivorans pathogenicity was attenuated by targeting CepR and inhibiting QS-controlled pathways. Scrutiny of the lead ligands allowed us to develop the first structure-activity relationships (SARs) for AHL-mediated CepR antagonism and agonism, which will provide a launching point for the design of yet more potent and potentially receptor selective ligands...
for CepR. These compounds represent valuable new chemical tools to study the role of CepR and QS in the virulence of Bcc members.

Results

Selection of compounds for testing. Our laboratory has previously reported the design, synthesis, and evaluation of several libraries of native AHLs, non-native AHL, and AHL-like compounds\textsuperscript{22,25,26,37}. We turned to these in-house libraries to identify modulators of CepR in the Bcc (see Fig. S1 for structures of the selected 169 compounds). The majority of these compounds contained a lactone “head group” with a variety of acyl “tail groups” that could presumably occupy the same space as C8-AHL in the CepR ligand-binding site, and thereby act as competitive agonists or antagonists.

Development of an \textit{E. coli} β-galactosidase reporter for cepR. We began our study by screening the AHL library for CepR modulators using an \textit{E. coli}-based two plasmid reporter system (Ec-reporter)\textsuperscript{38–40}. Certain members of the Bcc harbor additional QS systems that are either AHL-based (e.g., BviI/BviR in \textit{B. vietnamensis})\textsuperscript{41} or diffusible signal factor (DSF)-based (\textit{B. cenocepacia})\textsuperscript{42}, and at least one member of the Bcc has multiple receptors that respond to C8-AHL (e.g., CepR and CepR2 in \textit{B. cenocepacia})\textsuperscript{43}. Thus, we reasoned that using a CepR reporter in a heterologous background could simplify our initial analyses. We modified our previously reported \textit{E. coli}-based two plasmid \textit{β}-galactosidase reporter system to develop a CepR Ec-reporter (see Methods). The first plasmid, pJN105-cepR, contains CepR from \textit{B. cenocepacia} under the control of the L-arabinose inducible pBAD promoter. A second plasmid contains a transcriptional fusion of \textit{lacZ} to the cepI promoter region. The two plasmids were co-transformed into a QS mutant \textit{E. coli} strain (JLD271 [\textit{Δ}sdiA]) that lacks its LuxR-type receptor, SdiA. Using this reporter system, if an exogenously added compound is able to interact with CepR, this will affect the protein’s interaction with the \textit{cepI} promoter region and alter \textit{β}-galactosidase production. Enzyme production, and thereby CepR activity, is then measurable via the degradation of a colorimetric substrate for \textit{β}-galactosidase. Using this new Ec-reporter, we observed robust activity of CepR in response to its native ligand C8-AHL, with an EC\textsubscript{50} of 5 nM (Table 1).

| Compound | Maximal Activation (%) | EC\textsubscript{50} (nM) | 95% CI (nM)\textsuperscript{b} |
|----------|-----------------------|-----------------|-----------------|
| C8-AHL   | 100                   | 5.7             | 4.6–6.9         |
| 3-OH-C8-AHL | 84                  | 210             | 160–280         |
| 3O-C8-AHL | 86                   | 1200            | 720–2500        |
| D-3-O-C8-AHL | 85                | >27000          | —               |
| C\textsubscript{12}-AHL | 87                | 310             | 180–520         |
| C\textsubscript{14}-AHL | 98                | 310             | 180–520         |
| C\textsubscript{16}-AHL | 49                | —               | —               |
| 3’OH-C8-AHL | 35              | ≥27000          | —               |
| D-3’OH-C8-AHL | 85            | 1200            | 720–2500        |
| C\textsubscript{10}-AHL | 87                | 110             | 83–140          |
| C\textsubscript{12}-AHL | 98                | 310             | 180–520         |
| C\textsubscript{14}-AHL | 49                | —               | —               |
| C\textsubscript{16}-AHL | 35                | —               | —               |
| A11      | 5.0                   | —               | —               |
| A12      | 46                    | —               | —               |
| A13      | 110                   | 150             | 100–240         |
| B7       | 97                    | 0.29            | 0.14–0.59       |
| B9       | 88                    | 1000            | 590–2100        |
| B11      | 87                    | 130             | 85–200          |
| E26      | 96                    | 5.9             | 3.5–10          |
| E28      | 92                    | 3.8             | 1.7–8.2         |
| E29      | 92                    | 2.3             | 0.75–5.7        |
| E30      | 85                    | 4.4             | 3.0–6.4         |
| E31      | 89                    | 4.4             | 2.1–9.6         |
| E32      | 97                    | 1.1             | 0.75–1.7        |
| E33      | 92                    | 0.95            | 0.070–3.5       |
| E34      | 100                   | 0.071           | 0.029–0.13      |
| E35      | 100                   | 0.18            | 0.10–0.33       |
| E36      | 92                    | 26              | 15–48           |
| E37      | 95                    | 0.19            | 0.13–0.26       |
| E38      | 93                    | 660             | 380–1100        |
| E39      | 100                   | 1.4             | 0.49–3.4        |

Table 1. CepR agonism data for selected compounds in the \textit{E. coli} reporter\textsuperscript{a}. \textsuperscript{a}Compounds were evaluated in \textit{E. coli} reporter strain JLD271 [pN105-cepR + pSC11-cepI]. Activity for 100 nM C8-AHL set to 100%. All assays n ≥ 3. Maximal activation error = ±10%. See Methods for full details of assay methods. \textsuperscript{b}95% confidence interval for EC\textsubscript{50} value. \textsuperscript{c}Dose-response curve did not reach maximum plateau.
Regarding our choice of CepR for this Ec-reporter, B. cenocepacia is among the most common Bcc-isolate from CF patients. Further, there is high sequence similarity among both the cepR promoter sequences and the CepR protein sequences in Bcc member species (~76% and ~95%, respectively; Fig. S3), and the lux box is 100% conserved, suggesting compounds identified for CepR in B. cenocepacia will be effective in targeting CepR from other Bcc member species.

CepR agonism results in the Ec-reporter. We used the CepR Ec-reporter to perform a primary agonism screen at a single compound concentration (100μM), or its solubility limit, indicated in Table S1. Thirty-one compounds displaying ≥70% agonistic activity in CepR (relative to C8-AHL) were identified and subjected to dose-response analyses using the Ec-reporter (Table I; see Table S2 for complete screening data and Fig. S3 for dose-response curves). We focus our analyses here on the most potent CepR agonists found in these dose-response studies.

Overall, the most potent class of CepR agonists were phenylpropionyl homoserine lactones (PPHLS). In fact, 11 PPHL compounds were more potent agonists than C8-AHL, CepR’s native ligand (E34 > E35 ≈ E37 > B7 > E36; Table I). Strikingly, we found PPHL E34, with a para-methylsulfide substituent, was nearly 100-fold more potent than C8-AHL (Act % = 104, EC50 = 0.07 nM) in the Ec-reporter. Other notable CepR agonists that had sub-nanomolar potencies were E35, E37, B7, and E33. Overall, we found para-substituted PPHLS to be more potent than their meta-substituted analogs. For example, para-nitro PPHL E37 was a more potent agonist than its meta-substituted analog E38 (EC50 values of 0.19 nM vs. 660 nM, respectively), and this trend held true for E35 vs. E36, and B7 vs. E31, among others (Tables 1 and S1). Interestingly, these PPHL-type CepR agonists contained varied types of aryl substituents. Electron withdrawing groups, such as a nitro (E37) or trifluoromethyl (E35) group yielded potent agonists, as did electron donating groups, such as methoxy (E28) or methyl (E26) groups. However, it appears that some kind of substituent on the aryl group is necessary for potent CepR agonism, as the non-substituted PPHL (B9) had an EC50 > 1000 fold higher than those for substituted PPHLS. Replacement of the aryl group with a bulkier cyclohexyl group (to give B11) did lead to an increase in potency relative to B9, suggestive that stericus may be more important than electronics in this set of CepR agonists.

These assay data suggest that, out of the compounds screened, the PPHL scaffold is ideal for CepR activation, perhaps as it shares a similar tail length as the native ligand C8-AHL (~8 atoms). We observed that the incorporation of more or less atoms in the tail dramatically reduced compound potency. AHLs with 6, 10, and 12 carbons in the acyl chain only weakly to moderately activated CepR relative to C8-AHL (C6-AHL, Act % = 30, EC50 = 20000 nM; C10-AHL, Act % = 87, EC50 = 109 nM; and C12-AHL: Act % = 98, EC50 = 310 nM; Table S2), and longer acyl chain lengths were inactive (i.e., C14-AHL and C16-AHL). In most cases, compounds with tail lengths shorter than C8-AHL, for example, C4-AHL and C6-AHL, were considerably less agonistic and were actually CepR antagonists instead (see below).

The agonism assay data provided additional insights into CepR’s preference for AHL-type agonists. In congruence with previous findings for other LuxR-type receptors, the stereochemistry of the lactone ring was key to CepR activation, as compound B1, the d-isomer of C8-AHL, was inactive (Table S2). Sulfonamide AHL analogs also failed to activate CepR (i.e., A11, A12, and A13) and were found to antagonize CepR instead (see below; Table 2 and Fig. S3). Lastly, we found that a methylene at the 3-position of the acyl tail (as opposed to a 3-OH or 3-oxo) allowed for maximal CepR activation and potency (C7-AHL, Act % = 100, EC50 = 5.7 nM; 3’OH-C8-AHL, Act % = 84, EC50 = 210 nM; and 3’O-C7-AHL, Act % = 87, EC50 = 1200 nM; Table 1 and S2). None of the 20 lead CepR agonists were oxidized at carbon 3 of the tail.

CepR antagonism results in the Ec-reporter. To identify antagonists of CepR, we screened the AHL library (at 100 μM) in competition against the native ligand C8-AHL (at approximately twice its EC50 value, 0.01 μM) in the Ec-reporter. We found numerous strong CepR antagonists in the initial screen, with 23 compounds exhibiting ≥50% inhibition of CepR activity. The active compounds were subjected to dose-response analyses in the Ec-reporter to obtain IC50 values and assess their relative potencies (Table 2; see Table S3 for complete screening data and Fig. S3 for dose-response curves). One general trend that we noted at the outset was the majority of the antagonists had acyl tails of similar or shorter overall length than CepR’s native ligand, C8-AHL. From this set, the strongest antagonists could be divided into two classes: (i) “short alkyl tail” AHLs or analogs thereof, and (ii) phenylacetonitril HAs (PPHLs). The discovery that the latter compounds were CepR antagonists was perhaps not surprising, as we have found substituted PHLs to strongly antagonize the majority of the LuxR-type receptors studied in our laboratory to date. Interestingly, the unsubstituted PHL, C1, was recently reported to be the natural AHL signal used by the prosthete bacterium, Prosthecocibium hirschi submitting its structure, Prosthecocibium hirschi. The most potent CepR antagonists in the short-alkyl tail class were C12-AHL, C9-AHL, A11, A12, B12, and S4 (Tables 2 and S3). In this class, the most potent was the 8-atom tail sulfonamide analog of the native ligand C8-AHL. A12 (Act % = 68, IC50 = 3.38 μM). The 7-atom sulfonamide A11 was also a CepR antagonist, although 100-fold less potent than A12. The lead CepR antagonists in the PHL class were C8, C14, E3, E5, and E10, with the most potent PHLs displaying low micromolar IC50 values (Table 2). Having a substituent on the PHL aryl ring was critical to activity, as the unsubstituted PHL (and natural signal) C1 was inactive, paralleling the lack of agonistic activity for the unsubstituted PHL B9 (see above). However, for at least the PHLs tested here, neither the position nor the nature of the substituent on the PHL aryl group appeared to dramatically impact activity, ranging from electron-withdrawing (-Cl, C6) to electron-donating (-CH3, E7), although PHLs with fluorine in any position were inactive as antagonists (e.g., C2, C3, and C4; Table S3). The 3-nitro PHL C14 was among our most potent CepR antagonists; we previously have found C14 to display a diverse range of activities in LuxR-type receptors, ranging from being a highly potent agonist in LuxR (V. fisheri) and ExpR2 (P. carotovora) to a potent antagonist in LasR (P. aeruginosa). Intriguingly, we found that analogs of C14 with alternative head
groups exhibited dramatic losses in activity (e.g., thiolactone F10, cyclopentyl F18, phenyl F25, ethyl ester F40, and nitro-phenyl F35 analogs; Table S3). This trend suggests that the HL headgroup may be key to CepR antagonism by at least this PHL scaffold.

**Evaluation of lead CepR modulators in a member of the Bcc.** We next sought to assess if the CepR modulators identified in the Ec-reporter maintained their activities in a member of the Bcc. For these studies, we generated a *B. multivorans cepI::lacZ* reporter organism (Bm-reporter) using standard allelic exchange methods (see Methods). Along with *B. cenocepacia*, *B. multivorans* is one of the most commonly isolated Bcc members6,44. We note that small molecules must contend with a different cellular environment in the native organism relative to *E. coli*6; however, as both CepR and the cepI promoter are highly conserved among Bcc species (Fig. S3), we reasoned that the majority of compounds identified in the Ec-reporter (containing *B. cenocepacia* versions of the cepI promoter and the cepR gene) would maintain their relative activity profiles in CepR in *B. multivorans*. Our Bm-reporter organism had a genomic replacement of its synthase gene (*cepI* gene) would maintain their relative activity profiles in CepR in *B. cenocepacia* multivorans*, allowing for the quantitation of β-galactosidase. Similar to the Ec-reporter, CepR binding to the cepI promoter then induces β-galactosidase production, allowing for the quantitation of CepR activity. Using the Bm-reporter organism, we observed robust activity for CepR in response to C8-AHL (EC50 = 0.7 nM, Table 3).

We screened the most potent AHLs identified in the Ec-reporter in this new Bm-reporter. Structures of the lead CepR agonists and antagonists identified are shown in Fig. 2A,B, and the SAR trends are summarized in Fig. 2C,D. The PPHLs retained the strongest CepR agonistic activities in the Bm-reporter overall (E37 > E35 > E32 > E33 > B7 > E30 ≈ E26 ≈ C8-AHL). Most notably, we found *para*-nitro substituted PPHL E37 especially potent in the Bm-reporter, with an EC50 ~250-fold lower than C8-AHL (Act % = 91, EC50 = 0.0025 nM). This potency improvement relative to the native ligand is notable and represents the largest increase, along with the lowest EC50 value overall (single digit picoMolar), that we have measured in any LuxR-type receptor so far. When looking at overall potency trends between the Bm- and Ec-reporters, we note that the EC50 values were lower in the native organism; for example, the native ligand C8-AHL has an EC50 of 0.70 nM in the Bm-reporter, but has a ~10-fold higher EC50 (5.7 nM) in the Ec-reporter. PPHL E34 remained a potent agonist; however, its activity was much closer to that of C8-AHL in the Bm-reporter. Of the agonists tested in both reporter assays, only the potencies of 3’OH-C8-AHL, 3’O-C8-AHL, E31, and E36 were dramatically reduced in the Bm-reporter relative to the Ec-reporter.

Turning to the CepR antagonism data in the Bm-reporter, of the 10 most potent antagonists uncovered using the Ec-reporter, seven compounds remained in the top 10 in the Bm-reporter: A12, B12, C8, C14, E3, E7, and E25 (Table 4). C4-AHL and the cyclopentyl HL B12 were among the most potent antagonists in the Bm-reporter, supporting again that short-alkyl tails lead to CepR antagonism by AHLs. 3’-O-C8-AHL, the sole 3-oxo compound to have any activity in CepR, and the sulfonamide analog of C8-AHL, A12, both retained strong antagonistic activity in CepR. Likewise, PHLs C14, C8, E3, and E25 remain potent antagonists for CepR in *B. multivorans*. Most of these PHLs were meta-substituted, yet with variable substituents. Notably, several PHL antagonists were

| Compound | Maximal Inhibition (%) | IC50 (μM) | 95% CI (μM)b |
|----------|------------------------|-----------|--------------|
| C8-AHL   | 58                     | 20         | 15–28        |
| C6-AHL   | 83                     | 7.5        | 5.7–9.8      |
| 3’O-C8-AHL | 71                  | 16         | –            |
| A11      | 78                     | 11 h       | 5.1–22       |
| A12      | 68                     | 0.38       | 0.10–1.22    |
| B12      | 69                     | 3.7        | 2.7–5.2      |
| C6       | 66                     | 39         | 26–63        |
| C1       | 8                      | –          | –            |
| C7       | 89                     | 5.9        | –            |
| C8       | 79                     | 2.7        | 2.1–3.5      |
| C14      | 46                     | 1.4        | 0.30–11      |
| E3       | 77                     | 3.3        | 2.2–5.7      |
| E5       | 81                     | 2.7        | 1.2–10       |
| E7       | 76                     | 3.1        | 2.2–4.4      |
| E10      | 79                     | 0.43       | 0.20–1.1     |
| E25      | 70                     | 3          | 2.2–4.5      |
| S4       | 72                     | 32         | 18–63        |

**Table 2.** CepR antagonism data for selected compounds in the *E. coli* reporter.a *Compounds were evaluated in *E. coli* reporter strain JLD271 [p[N105-cepR + pSC11-cepI]. Activity for 100 μM C8-AHL set to 100%. All assays n ≥ 3. Maximal activation error = ±10%. See Methods for full details of assay methods. b CI = 95% confidence interval for IC50 value. c Dose-response antagonism curve showed inversion to agonism (i.e., non-monotonic behavior) at high compound concentrations. Concentrations at which CepR agonism was observed were excluded from IC50 calculations. See SI for additional details. d Curve did not reach minimum plateau. e |Hill behavior| at high compound concentrations.
able to bring reporter activity down to nearly zero in the Bm-reporter, with 3-bromo C8, 4-nitro C13, 3-CF3 E3, and 3-SMe E7 among the most potent of this group. Overall, our screening data in the two reporter systems, each with different CepR receptors, suggest that ligands identified as active in one CepR receptor can be utilized to modulate other CepR homologs. These data also validate the use of the heterologous strain to identify CepR ligands that maintain their activity profiles in a native Bcc species.

Swimming motility assays in *B. multivorans*. We were interested to assess the effects of our lead CepR modulators on a phenotype under the control of QS in *B. multivorans*. However, very little work has been reported

| Compound | Maximal Activation (%) | EC50 (nM) | 95% CI (nM)b |
|----------|------------------------|-----------|--------------|
| C8-AHL   | 100                    | 0.70      | 0.030–2.3c   |
| 3'OH-C8-AHL | 78               | >980d     | —            |
| 3'-O-C8-AHL | 72               | >3500d    | —            |
| B7       | 82                    | 0.24      | 0.11–0.64F   |
| CL       | 80                    | 940       | —            |
| E26      | 96                    | 0.60      | 0.1–69g      |
| E30      | 84                    | 0.75      | 0.26–2.3g    |
| E31      | 78                    | >3400d    | —            |
| E32      | 110                   | 0.080     | 0.029–0.24d  |
| E33      | 94                    | 0.15      | 0.028–0.56e  |
| E34      | 110                   | 0.94      | 0.45–2.1d    |
| E35      | 98                    | 0.022     | 0.0062–0.067c|
| E36      | 100                   | >3900d    | —            |
| E37      | 91                    | 0.0025    | 0.00020–0.0090d|

Table 3. CepR agonism data for selected compounds in the *B. multivorans* reporter. Compounds were evaluated in reporter strain *B. multivorans* cepI::lacZ. Activity for 100 μM C8-AHL set to 100%. All assays n ≥ 3. Error = ±10%. See Methods for full details of assay methods. bCI = 95% confidence interval for EC50 value. c|Hill slope| < 1.0, which affected 95% CI. dDose-response curve did not reach maximum plateau.
CepI/CepR in B. multivorans infection assays in C. elegans. We next assessed the effects of our lead CepR modulators on exacerbating or alleviating infections by a Bcc member using the nematode C. elegans as a model of pathogenicity. We infected N2 nematodes with B. multivorans ATCC17616 in the presence of compound, and assessed survival of worms over time (see Methods). None of the compounds tested caused measurable toxicity effects in uninfected worms under these conditions. Addition of CepR’s native ligand (C8-AHL) to Bm-infected worms significantly increased worm death relative to untreated worms (Fig. 4, p < 0.0001). Furthermore, addition of our strong CepR agonist E37 promoted worm killing in B. multivorans infected worms in a similar manner (p < 0.0001). Weak CepR agonist H2, however, did not appear to affect worm survival under these conditions (Fig. S5, p = 0.69). Strikingly, many of the most potent CepR antagonists prolonged nematode survival; we show representative examples in Fig. 4 (C8, B12, and E3; for full set of survival assay data, see Fig. S5). Several previous studies, using genetic approaches, have demonstrated the importance of QS to pathogenicity in nematode infections in other members of the Bcc genus. Our results here, using chemical CepR modulators, appear to replicate these effects in B. multivorans nematode infections. These data support chemical inhibition of CepR as a route to strongly attenuate virulence in a Bcc member.

Discussion

Chemical strategies to modulate CepR-mediated QS in Bcc species would provide an approach to study the role of this signaling process in Bcc infections with both spatial and temporal control. Such chemical approaches are scarce, however, and no synthetic antagonists that both directly target CepR and also affect QS-controlled phenotypes have been reported to date. Here, we report CepR agonism and antagonism data for a library of synthetic AHL analogs obtained using both an E. coli reporter and a B. multivorans reporter. These small molecule screens identified a set of highly potent CepR activators and inhibitors. Furthermore, our lead compounds have the ability to alter QS-controlled phenotypes in wild-type B. multivorans—namely swimming motility and the survival of infected nematodes—in a CepR-dependent manner. Some general trends in the types of AHL structures that elicit CepR activation or inhibition

| Compound | Maximal Inhibition (%) | IC50 (μM) | 95% CI (μM) |
|----------|------------------------|-----------|-------------|
| C8-AHL   | 76                     | 0.25      | 0.065–0.57  |
| C9-AHL   | 20                     | —         | —           |
| Yo-C8-AHL| 85                     | 0.80      | 0.20–62     |
| A12      | 82                     | 1.7       | 0.93–3.0    |
| B12      | 83                     | 2.1       | 1.1–3.3     |
| C8       | 94                     | 2.6       | 1.2–4.5     |
| CI3      | 96                     | 3.6       | 1.5 to 95   |
| CI4      | 54                     | 0.62      | 0.30–1.5    |
| E3       | 100                    | 1.9       | 1.1–3.9     |
| E5       | 43                     | —         | —           |
| E7       | 97                     | 4.0       | 2.2–13      |
| E10      | 21                     | —         | —           |
| E13      | 13                     | —         | —           |
| E25      | 83                     | 3.3       | 2.0–8.4     |
| S4       | 93                     | 3.7       | 1.5–20      |

Table 4. CepR antagonism data for selected compounds in the B. multivorans reporter. Compounds were evaluated in reporter strain B. multivorans cepI::lacZ. Activity for 100 μM C8-AHL set to 100%. All assays n ≥ 3. Error = ±10%. See Methods for full details of assay methods. 95% CI = 95% confidence interval for IC50 value. Dose–response antagonism curve showed inversion to agonism (i.e., non-monotonic behavior) at high compound concentrations. Concentrations at which CepR agonism was observed were excluded from IC50 calculations. See SI for additional details. Hill slope < 1.0, which affected 95% CI.

to directly link CepR activity in B. multivorans to any QS-controlled phenotype. Motility has been shown to be controlled partially (B. cenocepacia) or completely (B. cepacia K56-2) by the CepI/CepR system in other Bcc members, and the B. multivorans organism has been shown to be motile. Therefore, we chose to study the effects of compound treatment on both the swarming and swimming motility of B. multivorans (B. multivorans ATCC17616; see Methods).

Swarming motility (on 0.5% agar) was not increased upon addition of C8-AHL, suggesting swarming is not under the direct control of CepI/CepR in B. multivorans (Fig. S4). In contrast, we found that under our swimming conditions (on 0.3% agar), the addition of native ligand C8-AHL increased swimming radius in both the parental and cepI::lacZ organisms (Figs 3 and S4), suggesting swimming motility is at least partially under the control of CepI/CepR in B. multivorans. We then tested the ability of our non-native compounds to modulate swimming motility in B. multivorans. Motility increased upon treatment by three of our most potent CepR agonists, E32 (195%), E35 (175%), and E37 (173%), which was comparable to that by the native signal C8-AHL (182% relative to untreated sample, Fig. 3). In contrast, treatment with some of our strongest CepR antagonists, A12, B12, and E3, significantly decreased motility (55%, 53%, and 58%, respectively, relative to untreated sample). These results support that swimming motility in B. multivorans is at least partially under the control of the CepI/CepR QS system and that our compounds can be used to alter this behavior.

B. multivorans infection assays in C. elegans. We next assessed the effects of our lead CepR modulators on exacerbating or alleviating infections by a Bcc member using the nematode C. elegans as a model of pathogenicity. We infected N2 nematodes with B. multivorans ATCC17616 in the presence of compound, and assessed survival of worms over time (see Methods). None of the compounds tested caused measurable toxicity effects in uninfected worms under these conditions. Addition of CepR’s native ligand (C8-AHL) to Bm-infected worms significantly increased worm death relative to untreated worms (Fig. 4, p < 0.0001). Furthermore, addition of our strong CepR agonist E37 promoted worm killing in B. multivorans infected worms in a similar manner (p < 0.0001). Weak CepR agonist H2, however, did not appear to affect worm survival under these conditions (Fig. S5, p = 0.69). Strikingly, many of the most potent CepR antagonists prolonged nematode survival; we show representative examples in Fig. 4 (C8, B12, and E3; for full set of survival assay data, see Fig. S5). Several previous studies, using genetic approaches, have demonstrated the importance of QS to pathogenicity in nematode infections in other members of the Bcc genus. Our results here, using chemical CepR modulators, appear to replicate these effects in B. multivorans nematode infections. These data support chemical inhibition of CepR as a route to strongly attenuate virulence in a Bcc member.
are apparent (Fig. 2C,D). The most potent agonists contain aryl tail groups with various substitution patterns on the phenyl ring and a 2-carbon linker between the aryl ring and the amide bond. Among this class, the PPHL class stood out as a lead scaffold for CepR agonism. In turn, the most active CepR antagonists have an overall shorter acyl tail than the native ligand, C8-AHL, with various tail substituents, including aliphatic and phenylacetyl groups.

These SAR data for AHLs allowed us to consider potential mechanisms of action for their CepR agonism and antagonism. Agonism is perhaps the most straightforward to rationalize, as it is likely that these AHL derivatives act upon the same ligand-binding site in CepR as the native signal, C8-AHL. The only structural data of a C8-AHL-interacting LuxR-type receptor is for CepR2, consisting of an X-ray structure of its AHL-free, or “apo” ligand-binding domain. Glycerol was found to be present in CepR2’s putative AHL-binding site and engaged with two key residues (Thr 130 and Asp 76) that have been found to be important for AHL binding in other LuxR-type receptors. In view of this similarity, we hypothesize that CepR binds C8-AHL and our non-native agonists using the same, conserved subset of amino acids as other LuxR-type receptors. We predict that CepR:AHL

**Figure 3.** *B. multivorans* motility assay data. Swimming motility was measured by spotting *B. multivorans* plus compound indicated in the center of M9 + 0.1% casamino acids + 0.3% agar in a 10 cm diameter petri dish. Area of the colony after 72 h incubation was calculated using ImageJ, normalized to the *B. multivorans* wild-type + vehicle (DMSO), and listed above each plate shown.

**Figure 4.** *C. elegans* infection assay data. Survival analysis of *B. multivorans* (Bm)-infected *C. elegans* N2 with treatment of the compound as indicated. For both plots, red lines indicate C8-AHL treatment, black lines indicate vehicle (DMSO) treatment, gray lines indicate compound treatment (lines overlap) but no bacteria. See Fig. S5 for full data and statistical analyses. (A) Survival plots of Bm-infected worms in the presence of strong agonist E37 (green). (B) Survival plots of Bm-infected worms in the presence of antagonists C8 (green), B12 (blue) or E3 (yellow).
binding then leads to conformational changes within the protein to elicit homodimerization and downstream gene activation (similar to other LuxR-type receptors; see Fig. 1), and the 7–8 atom acyl chain length in our top CepR agonists is ideal for promoting such AHL-mediated CepR activation.

The mechanism of action for the CepR antagonists, however, remains ambiguous. The overall tail length of our most potent CepR antagonists was comparatively shorter than the native ligand. Plus, we observed that potent agonists could switch to antagonists by the subtraction of one carbon from the acyl chain (B7 vs. Control 7, E31 vs. C8, E37 vs. C13, E38 vs. C14, and E36 vs. E3 (Tables 1 and 2). These data suggest our antagonists may compete with the native ligand in binding CepR, yet upon binding cause different interactions that block activation. From here, whether the mechanism of CepR inhibition by these compounds is one of protein destabilization, as previously seen with LasR and QscR in P. aeruginosa, or protein stabilization in such a way as to inhibit its ability to bind DNA, as demonstrated with CviR from C. violaceum, or a combination of pathways or a new pathway entirely, will require further experimentation.

To close, the compounds identified herein constitute new chemical tools to study QS in Bcc species in a variety of contexts. Given the strong conservation of CepR between Bcc members, we hypothesize our compounds will maintain their activity profiles across Bcc member species and we can begin to use them to assess the role of CepI/CepR QS on a broader scale. In addition, these compounds could prove useful when investigating polymicrobial infections involving Bcc members; for example, co-infections between P. aeruginosa and Bcc species in the CF lung. A next step moving forward will be to gauge the selectivity of the ligands identified herein for CepR over other LuxR-type receptors. When comparing the activities of our lead compounds in CepR vs. the three LuxR-type receptors in P. aeruginosa (i.e., LasR, RhlR, and QscR)22,45,59, our preliminary analyses show that agonist E37, and antagonists A12 and E3 are selective for CepR over these receptors. Such compounds could allow for the selective targeting of QS in one organism in a mixed culture over time and allow for insights into the potential for interspecies interactions via QS and their effects on host health outcomes. Ongoing studies are focused in this arena, along with further delineating the mechanisms by which our CepI ligands agonize and antagonize CepR, and will be reported in due course.

Methods

Bacterial strains and growth conditions.

The bacterial strains and plasmids used in this study are summarized in Table S3. All biological media and reagents were obtained from commercial sources and used according to the manufacturer's instructions. E. coli JLD271, E. coli OP50, and B. multivorans were grown in LB (Research Products International) at 37 °C with shaking (at 225 rpm). Bacterial growth was assessed by measuring the culture absorbance at 600 nm (OD600) using a Biotek Synergy 2 microplate reader operating Gen5 data analysis software. The E. coli reporter was grown in Luria Bertani (LB) medium containing 100-μg/mL ampicillin and 15-μg/mL gentamicin. The B. multivorans reporter was also grown in LB medium. Freezer stocks of bacterial strains were maintained at −80 °C in 1:1 LB:glycerol. C. elegans N2 was propagated under standard conditions, synchronized by hypochlorite bleaching, and cultured on nematode growth medium using E. coli OP50 as a food source, as described previously.

Chemicals, reagents, and compound handling.

The non-native AHLs examined in this study were synthesized and purified as described previously. The structures of all of the compounds are shown in Fig. S1. C4-AHL, C6-AHL, 3’O-C6-AHL, C8-AHL, 3’O-C8-AHL, 3’O-C12-AHL were purchased from Sigma-Aldrich. Chlorophenol red-β-D-galactopyranoside (CPRG), the substrate for the β-galactosidase assays, was purchased from Santa Cruz Biotechnology, Inc. All enzymes were purchased from New England Biolabs and used according to manufacturer's instructions. Water (18 MΩ) was purified using a Millipore Feed System. Stock solutions of compounds were prepared in DMSO and stored at −20 °C in sealed glass vials. Final DMSO concentrations per well in biological assays did not exceed 1% (v/v). No compound had an effect on bacterial growth over the concentrations tested as gauged by monitoring OD600 over the time course of the assays.

Eclo-reporter plasmid construction.

The pSC11-cepI reporter plasmid was constructed from pSC11-L39, using B. cenocepacia genomic DNA as a template (ATCC BAA-245D-5). Primers (9-Sall-cepI*-F and 10-BamHI-cepI*-R) containing restriction sites for Sall and BamHI were used to amplify the cepI genomic region using OneTaq, digested with Sall and BamHI, and cloned into pSC11 digested with the same enzymes using Quick Ligase. pSC11-cepI was sequence verified. The pJN105-cepP plasmid was constructed by modifying pJN105-39. Primers (7-EcoRI-cepR-F and 8-XbaI-cepR-R) containing EcoRI and XbaI restriction sites were used to amplify cepR from B. cenocepacia genomic DNA (ATCC BAA-245D-5). The PCR product was digested with XbaI and EcoRI, then cloned into pJN105-L digested with the same enzymes using Quick Ligase. This plasmid was sequence verified (see Table 3; primers 2-pBADprom-F, 13-cepR-R2, and 14-cepR-F2).

B. multivorans cepI::lacZ reporter organism construction.

The B. multivorans cepI::lacZ strain was generated by replacing the native cepI with a promoterless lacZ. We first generated an intermediate plasmid, pEXG2 ΔcepI (GenScript), which had DNA fragments flanking the CepI ORF joined by two restriction enzyme recognition sequences, xbaI and scal. These sites were used to introduce Klenow-blunted XbaI- and Asel-cut lacZ from pUC18-miniTn7T-Gm-lacZ. The generated pEXG2 PcepI::lacZ plasmid was mated into B. multivorans ATCC17616 using the E. coli strain RH3, which requires diaminopimelic acid (DAP, added at 400 μg/mL final) for growth. B. multivorans exconjugants containing the chromosomally integrated pEXG2 PcepI::lacZ plasmid were isolated on LB agar plates using gentamicin at 300 μg/mL and no DAP for counterselection of E. coli. Strains in which the plasmid had excised were subsequently selected on no-salt LB agar plates containing 15% sucrose (no-salt LB agar plates containing 10 g bacto-tryptone, 5 g yeast extract, and 15 g agar/L of water). Mutants with the desired PcepI::lacZ allele were identified by the ability to turn blue on LB agar plates containing 40 μg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (to measure CepR-induced β-galactosidase production) and 10 μM C8-HSL (to activate CepR), and verified by PCR amplification and sequencing of the PCR products.
**E. coli** β-galactosidase reporter method. **E. coli** β-galactosidase reporter assays (derived from ref. 9) and reagents used to obtain primary screening and dose-response data were performed as previously described22,66, with the following modifications: **E. coli** JLD271 (AsiAlA) was co-transformed iteratively with pE151-cepR and p[pm105-cepR] via electroporation. A single colony was used to start overnight cultures in LB medium + ampicillin (100 μg/mL) + gentamicin (15 μg/mL). A 1:10 dilution of overnight culture was grown in fresh medium to OD₆₀₀ = 0.25. A sterile solution of l-arabinose in water (27 mM final concentration) was added to induce protein expression, after which cells were plated in 96-well plates containing varying concentrations of compound (200 μL total volume).

Cells were grown for 4 h, OD₆₀₀ was read, 50 μL aliquots from each well were permeabilized in 200 μL Z Buffer, and then 150 μL of this mixture used to measure the cleavage of 25 μL of 4 mg/mL CPRG in phosphate buffered saline (PBS) at 37 °C until positive control wells developed a deep red color (~30 min). For all agonism assays, synthetic compound (100 μM) was screened alongside and compared to the native ligand, C₈-AHL (100 μM). For all primary and dose-response antagonism assays, the concentration of native ligand utilized was 10 nM (approximately equal to twice its EC₅₀ value). IC₅₀ and EC₅₀ values, as well as 95% confidence intervals, were determined from sigmoidal curve fits using GraphPad Prism software (v.7.02, dose-response data found in Figs S3 and S4) using a variable slope parameter. At least 3 separate trials were performed using unique cultures on separate days.

**Burkholderia multivorans cepI::lacZ reporter assays.** The *B. multivorans cepI::lacZ* strain was used to obtain dose-response data for CepR in response to synthetic AHLs. Overnight cultures of *B. multivorans cepI::lacZ* were grown in LB medium at 37 °C with shaking (225 rpm). Aliquots (200 μL) of a 1:10 dilution of this overnight culture were plated into 96-well plates containing varying concentrations of compound, and then grown for 4 h at 37 °C with shaking (225 rpm). β-galactosidase production was measured as described above for *E. coli*, with the following changes: permeabilized cells were incubated at 25 °C with substrate CPRG for ~10 min until positive control wells developed a deep red color. For agonism assays, synthetic compound was screened alongside and compared to the native ligand, C₈-AHL (100 μM). For antagonism assays, the concentration of native ligand utilized was 5 nM (approximately equal to twice its EC₅₀ value).

**Motility assay.** The motility assay was based on a previously reported procedure32. *B. multivorans* was grown overnight with 50 μM compound at 37 °C and normalized to OD₆₀₀ = 0.4, and then cells were washed with sterile water and resuspended with 50 μM fresh compound. Cells (5 μL) were spotted in the center of M9 + 0.1% Casamino Acids + 0.3% agar plates (100 mm diameter). Cells were grown for 72 h at 37 °C. Images were analyzed using ImageJ to calculate the area of the colony and normalized to the area of *B. multivorans* wild-type + vehicle (DMSO).

**C. elegans survival assay.** The *C. elegans* survival assay was based on previously reported procedures35,65. To synchronize worms, eggs were harvested by hypochlorite bleaching (5 min in 1 mL 5% bleach, 0.25 mL 5 M NaOH, 3.75 mL H₂O), and grown on Nematode Growth Media (NGM) + *E. coli* OP50 at 21 °C. *B. multivorans* was grown overnight with the compound of interest in LB medium (1 μM for agonists, 50 μM for antagonists), and then the overnight culture was centrifuged, resuspended in the assay medium, standardized to OD₆₀₀ = 0.8, and 25 μL of this culture was used per condition. CFUs of these standardized cultures were used to confirm that bacteria numbers were relatively the same. For the survival assay, synchronized worms (L4 stage) were suspended in liquid NGM media containing bacteria and compound in 96-well plates (100 μL total volume). In all cases, DMSO volume did not exceed 1% of total volume. Plates were incubated at 25 °C, after which they were analyzed by a dissecting microscope. The fraction of dead worms was determined by scoring the number of dead worms and the total number of worms in each well. At least 30 nematodes were used for each well, and each assay was performed at least in duplicate on a single day (n ≥ 60). Survival assays were then repeated at least once on different days to verify patterns. Compound effect on worm survival rarely varied between replicates, but the overall worm susceptibility varied among assays. Kaplan-Meier survival curves were calculated using GraphPad Prism (v. 7.0) software.

**Data Availability**

The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

**References**

1. Govan, J. R., Brown, A. R. & Jones, A. M. Evolving epidemiology of *Pseudomonas aeruginosa* and the *Burkholderia cepacia* complex in cystic fibrosis lung infection. *Future Microbiol* 2, 153–164, https://doi.org/10.2217/17460913.2.2.153 (2007).
2. Peralta, D. P., Chang, A. Y., Ariza-Hutchinson, A. & Ho, C. A. The changing microbial epidemiology in cystic fibrosis. *Cystic Fibrosis Foundation*. Cystic Fibrosis Foundation. 2015 Annual Data Report. Bethesda, Maryland, https://www.cff.org/Our-Research/CF-Patient-Registry/2015-Patient-Registry-Annual-Data-Report.pdf (2016).
3. Lipuma, J. I. The changing microbial epidemiology in cystic fibrosis. *Clin Microbiol Rev* 23, 299–323, https://doi.org/10.1128/CMR.00068-09 (2010).
4. Stier, M. M. *Burkholderia cepacia* complex Infections: More Complex than the Bacterium Name Suggest. *J Infect*. https://doi.org/10.1016/j.jinf.2018.07.006 (2018).
5. Van Dalem, A. et al. In vitro susceptibility of *Burkholderia cepacia* complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam. *Antimicrob Agents Chemother*, https://doi.org/10.1128/AAC.00590-18 (2018).
6. Carnell, S. C. et al. Targeting the Bacterial Cytoskeleton of the *Burkholderia cepacia* Complex for Antimicrobial Development: A Cautionary Tale. *Int J Mol Sci* 19, https://doi.org/10.3390/ijms19061604 (2018).
7. Njoro, J. & Sperandio, V. Jamming bacterial communication: new approaches for the treatment of infectious diseases. *EMBO Mol Med* 1, 201–210, https://doi.org/10.1002/emmm.200900032 (2009).
44. Drevinek, P. & Mahenthiralingam, E.
41. Malott, R. J. & Sokol, P. A. Expression of the
36. Slachmuylders, L.
37. Mattmann, M. E., Shipway, P. M., Heth, N. J. & Blackwell, H. E. Potent and selective synthetic modulators of a quorum sensing
38. Lindsay, A. & Ahmer, B. M. Effect of sdiA on biosensors of
33. Riedel, K.
32. Brackman, G., Hillaert, U., Van Calenbergh, S., Nelis, H. J. & Coenye, T. Use of quorum sensing inhibitors to interfere with biofilm
30. Weingart, C. L.
26. Praneenararat, T., Geske, G. D. & Blackwell, H. E. Efficient synthesis and evaluation of quorum-sensing modulators using small
24. Geske, G. D., Mattmann, M. E. & Blackwell, H. E. Evaluation of a focused library of
23. Stacy, D. M., Welsh, M. A., Rather, P. N. & Blackwell, H. E. Attenuation of quorum sensing in the pathogen
14. Chapalain, A.
15. Sokol, P. A.
21. Mattmann, M. E.
17. McKeon, S. A., Nguyen, D. T., Viteri, D. F. & Sokol, P. A. Functional quorum sensing systems are maintained during
13. Kothe, M.
12. Subramoni, S. & Sokol, P. A. Quorum sensing systems influence Burkholderia cepaciaeia virulence. Future Microbiol 7, 1373–1387, https://doi.org/10.2217/fmb.12.118 (2012).
12. Smith, E. E. et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 103, 8487–8492, https://doi.org/10.1073/pnas.0602138103 (2006).
11. Hoffman, L. R. et al. Pseudomonas aeruginosa laxR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros 8, 66–70, https://doi.org/10.1016/j.jcf.2008.09.006 (2009).
10. Jiricny, N. et al. Loss of social behaviours in populations of Pseudomonas aeruginosa infecting lungs of patients with cystic fibrosis. PLoS One 9, e83124, https://doi.org/10.1371/journal.pone.0083124 (2014).
9. Mattmann, M. E. et al. Synthetic ligands that activate and inhibit a quorum-sensing regulator in Pseudomonas aeruginosa. Bioorg Med Chem Lett 18, 3072–3075, https://doi.org/10.1016/j.bmcl.2008.02.053 (2008).
8. Eibergen, N. R., Moore, J. D., Mattmann, M. E. & Blackwell, H. E. Potent and Selective Modulation of the RhlR Quorum Sensing Receptor by Using Non-native Ligands: An Emerging Target for Virulence Control in Pseudomonas aeruginosa. Chembiochem 16, 2348–2356, https://doi.org/10.1002/cbic.201500357 (2015).
7. Stacy, D. M., Welsh, M. A., Rather, P. N. & Blackwell, H. E. Attenuation of quorum sensing in the pathogen Acinetobacter baumannii using non-native N-acyl homoserine lactones. ACS Chem Biol 7, 1719–1728, https://doi.org/10.1021/cb800381x (2012).
6. Geske, G. D., Mattmann, M. E. & Blackwell, H. E. Evaluation of a focused library of N-aryl L-homoserine lactone inhibitors. Mol Microbiol 60, 553–567, https://doi.org/10.1111/j.1365-2958.2005.04656.x (2006).
5. Brackman, G. et al. Structure–activity relationship of cinnamaldehyde analogs as inhibitors of AI-2 based quorum sensing and their effect on virulence of Vibrio spp. PLoS One 6, e16084, https://doi.org/10.1371/journal.pone.0016084 (2011).
4. Brackman, G., Hillaert, U., Van Calenbergh, S., Nelis, H. J. & Coenye, T. Use of quorum sensing inhibitors to interfere with biofilm formation and development in Burkholderia multivorans and Burkholderia cepacia. Res Microbiol 160, 144–151, https://doi.org/10.1016/j.resmic.2008.12.003 (2009).
3. Praneenararat, T., Geske, G. D. & Blackwell, H. E. Efficient synthesis and evaluation of quorum-sensing modulators using small molecule macroarrays. Org Lett 11, 4600–4603, https://doi.org/10.1021/ol901871y (2009).
2. Palmer, A. G., Steng, E., Jewell, K. A. & Blackwell, H. E. Quorum sensing in bacterial species that use degenerate autoinducers can be used by structurally identical non-native ligands. Chembiochem 12, 138–147, https://doi.org/10.1002/cbic.201000551 (2011).
1. Palmer, A. G. et al. Intertokening Responses to Bacterial Quorum Sensing Signals Regulate Frequency and Rate of Nodulation in Legume–Rhizobium Symbiosis. Chembiochem 17, 2199–2205, https://doi.org/10.1002/cbic.201600373 (2016).

1. Li, C. B., Gao, H., Guo, Y., Zhang, H. & Wang, Y. The Role of Quorum Sensing in the Pathogenesis of Burkholderia ce"n"o"c"e"p"a"c"a"i"a. Future Microbiol 8, 1217–1231, https://doi.org/10.2217/fmb.13.118 (2013).
2. Sanadi, S. et al. Synthetic ligands that activate and inhibit a quorum-sensing regulator in Pseudomonas aeruginosa. Bioorg Med Chem Lett 18, 3072–3075, https://doi.org/10.1016/j.bmcl.2008.02.053 (2008).
3. Mattmann, M. E., Shipway, P. M., Heth, N. J. & Blackwell, H. E. Potent and selective synthetic modulators of a quorum sensing repressor in Pseudomonas aeruginosa identified from second-generation libraries of N-acylated L-homoserine lactones. Chembiochem 12, 942–949, https://doi.org/10.1002/cbic.201000708 (2011).
4. Lindsay, A. & Ahmer, B. M. Effect of sdiA on biosensors of N-acylhomoserine lactones. J Bacteriol 187, 5054–5058, https://doi.org/10.1128/JB.187.14.5054-5058.2005 (2005).
5. Chugani, S. A. et al. QscR, a modulator of quorum-sensing signal synthesis and virulence in Pseudomonas aeruginosa. Proc Natl Acad Sci USA 98, 2752–2757, https://doi.org/10.1073/pnas.0516242098 (2001).
6. Lee, J. H., Lequette, Y. & Greenberg, E. P. Activity of purified QscR, a Pseudomonas aeruginosa orphan quorum-sensing transcription factor. Mol Microbiol 59, 602–609, https://doi.org/10.1111/j.1365-2958.2005.04960.x (2006).
7. Malott, R. J. & Sokol, P. A. Expression of the qmsR and qpsR quorum-sensing systems of Burkholderia vietnamiensis. J Bacteriol 189, 3006–3016, https://doi.org/10.1128/JB.189.11.3006-3016.2007.
8. Boon, C. et al. A novel DSF-like signal from Burkholderia cepaciaeia interferes with Candida albicans morphological transition. ISME J 2, 27–36, https://doi.org/10.1038/ismej.2007.76 (2008).
9. Ryan, G. T., Wei, Y. & Winans, S. C. A LuxR-type repressor of Burkholderia cepaciaeia inhibits transcription via antisense and is inactivated by its cognate acylhomoserine lactone. Mol Microbiol 87, 94–111, https://doi.org/10.1111/mmi.12085 (2013).
10. Dreveník, P. & Mahenhiralingam, E. Burkholderia cepaciaeia in cystic fibrosis: epidemiology and molecular mechanisms of resistance. Clin Microbiol Infect 16, 821–830, https://doi.org/10.1111/j.1469-0691.2010.03237.x (2010).
11. Mattmann, M. E. & Blackwell, H. E. Small molecules that modulate quorum sensing and control virulence in Pseudomonas aeruginosa. J Org Chem 75, 6737–6746, https://doi.org/10.1021/doi101237e (2010).
46. Geske, G. D., O’Neill, J. C. & Blackwell, H. E. N-phenylacetanoyl-L-homoserine lactones can strongly antagonize or superagonize quorum sensing in Vibrio fisheri. ACS Chem Biol 2, 315–319, https://doi.org/10.1021/cb070036x (2007).
47. Liao, L. S., Schafer, A. L., Coutinho, B. G., Brown, P. J. B. & Greenberg, E. P. An aryl-homoserine lactone quorum-sensing signal produced by a dimorphic prosthecate bacterium. Proc. Natl. Acad. Sci. USA 115, 7587–7592, https://doi.org/10.1073/pnas.1808351115 (2018).
48. Moore, J. D., Gerdt, J. P., Eibergen, N. R. & Blackwell, H. E. Active efflux influences the potency of quorum sensing inhibitors in Pseudomonas aeruginosa. ChemBiochem 15, 435–442, https://doi.org/10.1002/cbic.201300701 (2014).
49. Schmid, N. et al. The AHL- and BDSF-dependent quorum sensing systems control specific and overlapping sets of genes in Burkholderia cenocepacia H111. PLoS One 7, e49966, https://doi.org/10.1371/journal.pone.0049966 (2012).
50. Lewenza, S., Visser, M. B. & Sokol, P. A. Interspecies communication between Burkholderia cepacia and Pseudomonas aeruginosa. Can. J Microbiol 48, 707–716 (2002).
51. Huber, B. et al. The cep quorum-sensing system of Burkholderia cepacia H111 controls biofilm formation and swarming motility. Microbiology 147, 2517–2528, https://doi.org/10.1099/00221287-147-9-2517 (2001).
52. Bernier, S. P. et al. Pseudomonas aeruginosa-Derived Rhamnolipids and Other Detergents Modulate Colony Morphotype and Motility in the Burkholderia cepacia Complex. J Bacteriol 199, https://doi.org/10.1128/JB.00171-17 (2017).
53. Cooper, V. S., Carlson, W. A. & Lipuma, J. J. Susceptibility of Caenorhabditis elegans to Burkholderia infection depends on prior diet and secreted bacterial attractants. PLoS One 4, e7961, https://doi.org/10.1371/journal.pone.0007961 (2009).
54. Huber, B. et al. Identification of a novel virulence factor in Burkholderia cenocepacia H111 required for efficient slow killing of Caenorhabditis elegans. Infect Immun 72, 7220–7230, https://doi.org/10.1128/IAI.72.12.7220-7230.2004 (2004).
55. Kim, Y. et al. X-ray Crystal Structures of the Pheromone-binding Domains of Two Quorum-Hindered Transcription Factors, YenR of Yersinia enterocolitica and CepR2 of Burkholderia cepacia. Proteins, https://doi.org/10.1002/pro.25536 (2017).
56. Bottomley, M. J., Muraglia, E., Razzo, R. & Carfi, A. Molecular insights into quorum sensing in the human pathogen Pseudomonas aeruginosa from the structure of the virulence regulator LasR bound to its autoinducer. J Biol Chem 282, 13592–13600, https://doi.org/10.1074/jbc.M700556200 (2007).
57. Wysocki-S-Horita, C. L. et al. Mechanism of agonism and antagonism of the Pseudomonas aeruginosa quorum sensing regulator QscR with non-native ligands. Mol Microbiol 108, 240–257, https://doi.org/10.1111/mmi.13930 (2018).
58. Chen, G. et al. A strategy for antagonizing quorum sensing. Mol Cell 42, 199–209, https://doi.org/10.1016/j.molcel.2011.04.003 (2011).
59. Geske, G. D. et al. Comparative analyses of N-acylated homoserine lactones reveal unique structural features that dictate their ability to activate or inhibit quorum sensing. ChemBioChem 9, 389–400, https://doi.org/10.1002/cbic.200700551 (2008).
60. O’Reilly, M. C. & Blackwell, H. E. Structure-Based Design and Biological Evaluation of Triphenyl Scaffold-Based Hybrid Compounds as Hydrolytically Stable Modulators of a LuxR-Type Quorum Sensing Receptor. ACS Infect Dis 2, 32–38, https://doi.org/10.1021/acsiinfec.5b00112 (2016).
61. Choi, K. H. & Schweizer, H. P. mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa. Nature Protocols 1, 153–161, https://doi.org/10.1038/nprot.2006.24 (2006).
62. Lopez, C. M., Kroll, D. A., Trunck, L. A. & Schweizer, H. P. Versatile dual-technology system for markerless allele replacement in Burkholderia pseudomallei. Appl Environ Microbiol 75, 6498–6503, https://doi.org/10.1128/AEM.06669-09 (2009).
63. Griffith, K. L. & Wolf, R. E. Jr. Measuring bete-galactosidase activity in bacteria: cell growth, permeabilization, and enzyme assays in 96-well arrays. Biochem Biophys Res Commun 290, 397–402, https://doi.org/10.1006/bbrc.2001.6152 (2002).
64. Welsh, M. A., Eibergen, N. R., Moore, J. D. & Blackwell, H. E. Small molecule disruption of quorum sensing cross-regulation in Pseudomonas aeruginosa causes major and unexpected alterations to virulence phenotypes. J Am Chem Soc 137, 1510–1519, https://doi.org/10.1021/ja5118076 (2015).
65. O’Loughlin, C. T. et al. A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc. Natl. Acad. Sci. USA 110, 17981–17986, https://doi.org/10.1073/pnas.1316981110 (2013).

Acknowledgements
Financial support for this work was provided by the NIH under Award Numbers R01 GM109403 and R35 GM131817 (to H.E.B.) and P20 GM103638 (to J.R.C.). B.L.S. was supported in part by an NIH Ruth Kirschstein National Research Service Award under Award Number F32 AI138918. N2 strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs under Award Number P40 OD010440. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author Contributions
B.L.S. and H.E.B. conceived of this research project. B.L.S prepared the E. coli CepR reporter and performed all of the experiments with small molecules. J.R.C. and J.J.D. prepared the B. multivorans CepR reporter strain. B.L.S., H.E.B. and J.R.C. analyzed the data, and B.L.S., H.E.B. and J.R.C. wrote and edited the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-49693-x.

Competing Interests: The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2019